Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study
暂无分享,去创建一个
R. Foà | E. Orlandi | F. Efficace | G. Caocci | C. Fozza | M. Breccia | F. Albano | L. Luciano | M. Tiribelli | F. Stagno | M. Bonifacio | S. Galimberti | F. Castagnetti | G. Gugliotta | A. Iurlo | C. Baratè | M. Trawinska | E. Abruzzese | C. Elena | O. Mulas | M. Annunziata | N. Sgherza | P. Pregno | G. Binotto | A. Gozzini | I. Capodanno | D. Luzi | M. P. Simula | L. Scaffidi | Fiorenza De Gregorio | D. Cattaneo | I. Attolico | F. Pirillo | R. Stella | E. Scalzulli | G. Nasa
[1] L. Tokgözoğlu,et al. Lipid Modification to Reduce Cardiovascular Risk in Secondary Prevention Patients with Special Emphasis on PCSK9 Inhibitor Requirement: An Analysis Based on Delphi Panel Approach. , 2022, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[2] J. Pinilla-Ibarz,et al. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. , 2020, Blood advances.
[3] G. Hindricks,et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.
[4] M. Sabatine,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.
[5] R. Foà,et al. Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. , 2019, International journal of cardiology.
[6] R. Foà,et al. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart , 2019, Hematological oncology.
[7] Deepak L. Bhatt,et al. Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease , 2019, JAMA.
[8] Z. Korade,et al. Identification and characterization of prescription drugs that change levels of 7-dehydrocholesterol and desmosterol[S] , 2018, Journal of Lipid Research.
[9] Martin C. Müller,et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. , 2018, Blood.
[10] J. Jukema,et al. The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model , 2018, Front. Cardiovasc. Med..
[11] G. Rosti,et al. Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission , 2018, Front. Oncol..
[12] M. Breccia,et al. Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option , 2018, Clinical Drug Investigation.
[13] Lale Tokgözoğlu,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.
[14] J. Borén,et al. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity , 2016, Current opinion in lipidology.
[15] M. Baccarani,et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia , 2016, Leukemia.
[16] C. Carcassi,et al. Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. , 2015, Experimental hematology.
[17] J. Guyton,et al. Intermittent Nondaily Dosing Strategies in Patients with Previous Statin-Induced Myopathy , 2013, The Annals of pharmacotherapy.
[18] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.
[19] G. Boysen,et al. European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.
[20] L. Martorana,et al. Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia , 2008, Leukemia.
[21] R. Krauss,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease , 2018 .
[22] A. Hoes,et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.
[23] A. Hoes,et al. [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.